Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.78 |
| ▸ | DRD4 | P21917 | 5/20 | 0.78 |
| ▸ | DRD3 | P35462 | 5/20 | 0.78 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16827643 | 0.86 | DRD2 (0.76) | DRD2DRD4DRD3NOTUML3MBTL1 | |
| SCHEMBL16827655 | 0.83 | DRD2 (0.67) | DRD2DRD4DRD3 | |
| SCHEMBL16835102 | 0.82 | DRD2 (0.78) | DRD2DRD4DRD3NOTUMMAOA | |
| SCHEMBL18352418 | 0.81 | DRD2 (0.68) | DRD2DRD4DRD3NOTUMMAOA | |
| SCHEMBL6014209 | 0.81 | DRD4 (0.84) | DRD2DRD4DRD3L3MBTL1TRPV1 | |
| SCHEMBL18357887 | 0.79 | DRD2 (0.63) | DRD2DRD4DRD3CACNA2D1 | |
| SCHEMBL16828015 | 0.78 | DRD2 (0.62) | DRD2DRD4DRD3CACNA2D1 | |
| SCHEMBL2660374 | 0.78 | DRD4 (0.72) | DRD2DRD4DRD3ADRA2C | |
| SCHEMBL16827615 | 0.76 | DRD2 (0.60) | DRD2DRD4DRD3CACNA2D1 | |
| SCHEMBL18357888 | 0.76 | DRD2 (0.60) | DRD2DRD4DRD3NOTUMMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745361-B2 | Piperazine derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-08-18 | — | — | US | disclosed |
| US-20190276415-A1 | PIPERAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2019-09-12 | — | — | US | disclosed |
| US-10351535-B2 | Piperazine derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-07-16 | — | — | US | disclosed |
| US-20170001967-A1 | PIPERAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-01-05 | — | — | US | disclosed |
| US-20170001967-A1 | PIPERAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-01-05 | — | — | US | disclosed |
| EP-3083563-A1 | PIPERAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015092009-A1 | PIPERAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745361-B2 | Piperazine derivatives having multimodal activity against pain | OPRD1, OPRM1, OPRL1 | DRD2 46/4885DRD4 198/4885DRD3 73/4885 |
| US-20190276415-A1 | PIPERAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, OPRM1, OPRL1 | DRD2 46/4885DRD4 198/4885DRD3 73/4885 |
| US-20170001967-A1 | PIPERAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRM1, OPRD1, OPRK1 | DRD2 59/4885DRD4 241/4885DRD3 117/4885 |
| US-10351535-B2 | Piperazine derivatives having multimodal activity against pain | OPRM1, OPRD1, OPRK1 | DRD2 59/4885DRD4 241/4885DRD3 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.